These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30103321)

  • 1. Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.
    Segovia F; Gómez-Río M; Sánchez-Vañó R; Górriz JM; Ramírez J; Triviño-Ibáñez E; Carnero-Pardo C; Martínez-Lozano MD; Sopena-Novales P
    J Alzheimers Dis; 2018; 65(3):765-779. PubMed ID: 30103321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-Phase 18F-Florbetaben PET as an Alternative Modality for 18F-FDG PET.
    Son SH; Kang K; Ko PW; Lee HW; Lee SW; Ahn BC; Lee J; Yoon U; Jeong SY
    Clin Nucl Med; 2020 Jan; 45(1):e8-e14. PubMed ID: 31524679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
    Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coupled Imaging with [
    Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
    Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
    Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
    J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET.
    Brendel M; Schnabel J; Schönecker S; Wagner L; Brendel E; Meyer-Wilmes J; Unterrainer M; Schildan A; Patt M; Prix C; Ackl N; Catak C; Pogarell O; Levin J; Danek A; Buerger K; Bartenstein P; Barthel H; Sabri O; Rominger A
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2239-2248. PubMed ID: 28932894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Correlation of Static First-Minute-Frame (FMF) PET Imaging after
    Seiffert AP; Gómez-Grande A; Villarejo-Galende A; González-Sánchez M; Bueno H; Gómez EJ; Sánchez-González P
    Sensors (Basel); 2021 Jul; 21(15):. PubMed ID: 34372416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A deep learning model for generating [
    Sanaat A; Boccalini C; Mathoux G; Perani D; Frisoni GB; Haller S; Montandon ML; Rodriguez C; Giannakopoulos P; Garibotto V; Zaidi H
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3518-3531. PubMed ID: 38861183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
    Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
    PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
    Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.
    Kemppainen N; Joutsa J; Johansson J; Scheinin NM; Någren K; Rokka J; Parkkola R; Rinne JO
    J Alzheimers Dis; 2015; 48(1):123-33. PubMed ID: 26401934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.